Form 8-K - Current report:
SEC Accession No. 0001437749-17-017777
Filing Date
2017-10-30
Accepted
2017-10-30 08:41:01
Documents
21
Period of Report
2017-10-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.01: Changes in Control of Registrant
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K avir20171027_8k.htm 8-K 53601
2 EXHIBIT 2.1 ex_97866.htm EX-2.1 743946
3 EXHIBIT 2.2 ex_97868.htm EX-2.2 44242
4 EXHIBIT 2.3 ex_97867.htm EX-2.3 39890
5 EXHIBIT 99.1 ex_98056.htm EX-99.1 31743
6 EXHIBIT 99.2 ex_98060.htm EX-99.2 7368
7 EXHIBIT 99.3 ex_98061.htm EX-99.3 18684
8 slide12.jpg GRAPHIC 132933
9 slide11.jpg GRAPHIC 122525
10 slide10.jpg GRAPHIC 138990
11 slide09.jpg GRAPHIC 141998
12 slide08.jpg GRAPHIC 138136
13 slide07.jpg GRAPHIC 125097
14 slide06.jpg GRAPHIC 132680
15 slide05.jpg GRAPHIC 120388
16 slide04.jpg GRAPHIC 80621
17 slide03.jpg GRAPHIC 203303
18 slide02.jpg GRAPHIC 198292
19 slide01.jpg GRAPHIC 80531
20 aviragen.jpg GRAPHIC 13484
21 vaxart.jpg GRAPHIC 11622
  Complete submission text file 0001437749-17-017777.txt   3191002
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35285 | Film No.: 171160761
SIC: 2836 Biological Products, (No Diagnostic Substances)